Need a Real Risk-Taking Commercializer?
Unlike other technology-transfer companies, which license technologies they’ve acquired or charge fees to broker deals, UTEK pays the research lab for licensing rights to its discovery. It then sells those rights to the client company for shares of stock, which UTEK agrees to hold for one year. UTEK might pay $500,000 for the discovery and receive stock worth $2.5M . A lot can happen in a yearUTEK’s stake in ZTrim, for example, ballooned to $6M. On the other hand, in a dozen deals since the company’s inception in 1997, the client company ceased operations, and UTEK’s stake evaporated.
